Gerald Dimaso, MD
Internal Medicine · Staten Island, NYNPI 1477526531
Payments from drug & device makers
Across 969 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$2K
- AbbVie$1K
- GSK$1K
- Lilly USA, LLC$1K
- Novartis$893
- plus $6K from 30 others
What the payments were for
- Food & beverage$15,31999%
- Education$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 128 | $2,581 |
| Novo Nordisk | 144 | $2,163 |
| AbbVie(2 entities) | 87 | $1,258 |
| GSK | 78 | $1,151 |
| Lilly USA, LLC | 72 | $1,121 |
| Novartis | 44 | $893 |
| Merck | 54 | $739 |
| Amgen(2 entities) | 42 | $639 |
| Amarin Pharma, Inc. | 34 | $548 |
| Johnson & Johnson | 34 | $504 |
| Bayer | 25 | $480 |
| Kowa Pharmaceuticals America, Inc. | 35 | $452 |
| Pfizer | 38 | $433 |
| Boehringer Ingelheim | 25 | $387 |
| Esperion Therapeutics, Inc. | 23 | $343 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $223 |
| Abbott | 13 | $204 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $201 |
| Astellas Pharma US Inc | 3 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $139 |
| Sanofi-aventis U.S. LLC | 10 | $138 |
| Dexcom, Inc. | 7 | $131 |
| Xeris Pharmaceuticals, Inc. | 5 | $100 |
| Lundbeck LLC | 5 | $94 |
| Exact Sciences | 4 | $93 |
| E.r. Squibb & Sons, L.L.C. | 6 | $83 |
| Circassia Inc. | 3 | $39 |
| Bausch Health US, LLC | 2 | $31 |
| Heartflow, Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Optinose US, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,439 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 177 | $224,987 |
| JardianceEmpagliflozin | 103 | $133,436 |
| FarxigaDapagliflozin Propanediol | 101 | $119,374 |
| EliquisApixaban | 96 | $112,011 |
| JanumetSitagliptin Phos/Metformin Hcl | 87 | $95,401 |
| RybelsusSemaglutide | 42 | $93,913 |
| XareltoRivaroxaban | 80 | $84,865 |
| JanuviaSitagliptin Phosphate | 77 | $83,000 |
| MounjaroTirzepatide | 73 | $81,597 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $36,556 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $29,290 |
| TrulicityDulaglutide | 18 | $25,858 |
| LinzessLinaclotide | 37 | $25,184 |
| ProliaDenosumab | 13 | $22,457 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $20,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,163 | $318,900219 claims |
| MerckJanumet, Januvia | $739 | $178,401164 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Jentadueto Xr | $387 | $145,877128 claims |
| AstraZenecaFarxiga, Symbicort | $2,581 | $126,601114 claims |
| PfizerEliquis | $433 | $112,01196 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,121 | $107,45491 claims |
| GSKAnoro Ellipta, Breo Ellipta, Trelegy Ellipta | $1,151 | $85,939131 claims |
| Johnson & JohnsonXarelto | $504 | $84,86580 claims |
| AbbVieLinzess, Synthroid | $1,258 | $31,017148 claims |
| AmgenProlia | $639 | $22,45713 claims |
| NovartisEntresto | $893 | $19,19612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $223 | $9,24613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Staten Island
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.